Grifols (NASDAQ:GRFS) Rating Lowered to "Hold" at Wall Street Zen

Key Points

• Wall Street Zen downgraded Grifols from “Buy” to “Hold.” The broader analyst consensus is “Reduce,” with two Hold ratings and one Sell rating, and an average price target of $10.00.
• Grifols shares opened at $7.46, near their 50-day and 200-day moving averages, with a 12-month trading range of $6.96 to $9.90 and a market capitalization of approximately $5.08 billion.
• Several institutional investors increased their Grifols holdings, including Quantinno Capital Management, which raised its position by 42%, and Flat Footed LLC, which increased its stake by 26.5%.

Grifols (NASDAQ:GRFS - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a research note issued to investors on Saturday, Wall Street Zen reports.

A number of other brokerages have also weighed in on GRFS. Zacks Research upgraded Grifols from a "strong sell" rating to a "hold" rating in a report on Tuesday, July 7th. Weiss Ratings raised shares of Grifols from a "sell (d)" rating to a "sell (d+)" rating in a report on Monday, August 17th. Two research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Reduce" and an average price target of $10.00.

Grifols Price Performance

Shares of Grifols stock opened at $7.46 on Friday. The business has a 50 day simple moving average of $7.67 and a two-hundred day simple moving average of $7.74. Grifols has a 12 month low of $6.96 and a 12 month high of $9.90. The stock has a market capitalization of $5.08 billion, a P/E ratio of 39.26, a PEG ratio of 0.27 and a beta of 0.70. The company has a debt-to-equity ratio of 1.10, a current ratio of 2.37 and a quick ratio of 0.81.

Institutional Trading of Grifols

A number of hedge funds and other institutional investors have recently modified their holdings of GRFS. Flat Footed LLC lifted its stake in shares of Grifols by 26.5% in the 1st quarter. Flat Footed LLC now owns 1,372,394 shares of the biotechnology company's stock valued at $11,007,000 after purchasing an additional 287,867 shares during the last quarter. Tidal Investments LLC boosted its stake in Grifols by 9.8% during the second quarter. Tidal Investments LLC now owns 1,233,082 shares of the biotechnology company's stock worth $8,730,000 after buying an additional 109,612 shares during the period. Quantinno Capital Management LP increased its position in shares of Grifols by 42.0% during the first quarter. Quantinno Capital Management LP now owns 352,798 shares of the biotechnology company's stock valued at $2,829,000 after acquiring an additional 104,418 shares during the last quarter. Royal Bank of Canada increased its position in shares of Grifols by 15.4% during the first quarter. Royal Bank of Canada now owns 785,703 shares of the biotechnology company's stock valued at $6,301,000 after acquiring an additional 104,850 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. raised its stake in shares of Grifols by 13.8% in the 2nd quarter. Hennion & Walsh Asset Management Inc. now owns 592,173 shares of the biotechnology company's stock valued at $4,193,000 after acquiring an additional 72,037 shares during the period.

Grifols Company Profile

Grifols SA is a global healthcare company based in Barcelona, Spain, and is listed on Nasdaq under the symbol GRFS. Founded in 1909, the company is primarily focused on developing, manufacturing and supplying plasma-derived medicines and other healthcare products.

Its principal therapies include immunoglobulins, albumin, alpha-1 antitrypsin and coagulation factors, which are used to treat immune deficiencies, respiratory disorders, bleeding conditions and other serious diseases. Grifols operates a network of plasma donation centers, mainly in the United States and Europe, to collect the source plasma used in its medicines.

Grifols also provides diagnostic solutions, including instruments and reagents used in blood typing, transfusion medicine and laboratory testing.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.